BioNeutral Discusses Their Anti-Microbial And Disinfecting Products On NBC Channel 4 New York And News 12 New Jersey

Dr. Andy Kielbania, Ph.D., Chief Scientist, of BioNeutral Group, Inc. (OTCBB: BONU) appeared on News 12 New Jersey on November 16 and both Dr. Kielbania and Stephen J. Browand, President and CEO, appeared on NBC Channel 4 New York on November 29. The interviews were conducted at their laboratory at the New Jersey Institute of Technology in Newark, NJ.

The segments highlight the life science company’s environmentally friendly product platforms, Ygiene™ and Ogiene™, which include technologies that have been independently tested to eradicate harmful microorganisms essentially on contact. Dr. Kielbania provides a demonstration of the effectiveness of their multi-purpose cleaner and speaks to the many applications the chemistry-based technologies will have if approved by the Environmental Protection Agency (EPA).

Commenting on the interview, CEO Stephen Browand said, “The programs were a great opportunity for BioNeutral to share the future applications of its technologies. What we have created at our lab in New Jersey has the potential to wipe out many life threatening microorganisms, including MRSA, C. diff, H1N1 and even anthrax.”

View these segments below:

Anti-Bacterial Hand Gels (NBC Channel 4 New York)

Swine Flu (News 12 New Jersey) 

About BioNeutral
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene and Ogiene, which are eco-friendly and include natural and common ingredients found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.  
 

Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene and are not yet available for sale in the United States.

Under the Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes”, and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of BioNeutral Group can be found in the filings of BioNeutral Group with the U.S. Securities and Exchange Commission.